Pharmafile Logo

The risk of replicating social bias in synthetic patient data – The need for human intelligence partnered with AI

Authored by Paul Reed and Anabelle Gall

- PMLiVE

As we move forward in 2024, the healthcare industry has embraced the idea that AI-generated synthetic patients are here for the long haul. The remarkable ability to utilize artificial patients that mimic real-world patient data addresses crucial unmet needs, making it nearly impossible to envision a future healthcare industry without widespread usage and integration of synthetic patients.

However, we must strike a delicate balance between integrating AI tools into market research and acknowledging the invaluable role of human intelligence in understanding, verifying, supervising and analysing insights. In this article, we delve into the compelling arguments surrounding the opportunities and risks associated with the utilization of AI-generated synthetic patients in healthcare market research.

Read the full article here. 

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

AAD conference 2016

Therapy Watch recently presented “real-world” patient data on treatment duration and persistence among European PsO patients

Video: Global Biosimilars Market

Research director of Therapy Watch, Laurent Chanroux, discusses the growth opportunities for biosimilars and the importance of adaptable market tracking for pre and post product launch

Case study: Understanding Patient Willingness to Pay in Emerging Markets

Our client wanted to identify the optimum selling price for their chronic disease treatment in emerging markets, based on patient’s willingness to pay for the product out of pocket.Find out...

From promise to practice: immuno-oncology in action Part 3 – Emerging Markets

Our latest white paper on immuno-oncology explores the challenges and opportunities in emerging markets, with a focus on Asia.

Infographic: HCV EU

Research findings from our Therapy HCV study shows that 28% of HCV patients in the EU are infected by sharing needles or drug equipment.Our latest market snapshot offers an introduction...

Taiwan: Exploring the Healthcare Opportunity in this Singular “Hybrid” Market

Published in eyeforpharma February 2016 by Rachel Howard

Gaining deeper insights within a hard to reach audience

Often a short research study isn’t sufficient to get the level of insights and understanding that you require, especially when working with a hard to reach target audience.It can also...

Living with RA Report

Living with Rheumatoid Arthritis 2016 is a new syndicated report which offers low-cost, high-value quantitative insight into patient attitudes and behaviour.

Heather Desmet appointed new Head of Living With

We are delighted to welcome Heather Desmet as Head of Living With at the company’s London headquarters.

Webinar Recording: The Art of Storytelling in Pharma Market Research

Effectively communicating research insights is a major focus for today’s market researcher, particularly in global healthcare. It’s not enough now just to present the research evidence. We must tell the...